Skip to main content
. Author manuscript; available in PMC: 2010 Aug 2.
Published in final edited form as: Int J Radiat Oncol Biol Phys. 2008 Aug 23;73(3):699–708. doi: 10.1016/j.ijrobp.2008.05.034

Table 6.

Steroid Use at 3 months for the First 14 (if available) Registered Progression-Free Survival Patients

Group 1 (PTV2< 75 cc) Group 2 (PTV2 ≥ 75 cc)
66 Gy
(n=14/16*)		 72 Gy
(n=14/16)		 78 Gy
(n=14/22)		 84 Gy
(n=14/17)		 66 Gy
(n=14/22)		 72 Gy
(n=11/11)		 78 Gy
(n=14/27)		 84 Gy
(n=10/10)
Yes 9 (64%) 5 (36%) 7 (50%) 7 (50%) 10 (71%) 6 (55%) 4 (29%) 5 (50%)
No 5 (36%) 9 (64%) 7 (50%) 7 (50%) 4 (29%) 5 (45%) 10 (71%) 5 (50%)
*

The numerator is the first 14, if available, registered and progression-free patients and the denominator is the total number of progression-free patients at 3 in that RX arm.